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We have had three discussions this afternoon 
concerning amenorrhea. and most of these have dealt 
with the diagnosis of causative conditions. I am going 
to discuss the treatment of these women. 
Whether or not the woman wishes to conceive in 
the immediate future determines the plan of treat­
ment in most cases. If conception is desired. I believe 
it should not be immediately assumed that the 
amenorrhea is the sole cause of the infertility. I would 
check patency of fallopian tubes and adequacy of the 
husband's sperm production before treating for con­
ception. Regardless of the plans for pregnancy. 
however. it should be determined whether the woman 
is merely not ovulating with adequate endogenous 
ovarian estrogen production or whether the ovula­
tory failure is associated with lack of estrogen as well. 
The former might occur if pituitary gonadotropins 
were reduced and/or the preovulatory LH surge were 
absent. The latter condition may be due to failure 
of production of pituitary gonadotropins or to meno­
pause with elevated levels of pituitary gonadotropins. 
Several brief case reports of women with 
amenorrhea will follow. In some of these. there will 
be organic disease of the extragenital endocrine 
glands such as the thyroid gland, or the adrenal 
gland, or the pituitary gland. In others, there will be 
no identifiable extragenital endocrine disease: then 
the treatment would vary depending on whether or 
not the woman wishes to become pregnant. 
Case I. This patient was a 35-year-old gravida I. 
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para I. aborta O who was seen after having amenor­
rhea for six months. She had noticed tachycardia, 
sweats. and weight loss. The radioactive iodine 
uptake was 80% in 24 hours: this is much higher than 
normal for this laboratory. A diagnosis of hyper­
thyroidism was made. The patient was treated with 
radioactive iodine and had resumption of regular 
menses after the second course of treatment. She is 
not presently trying to become pregnant. 
In preparing for this talk. I was looking for in­
stances of thyroid disease that caused amenorrhea, 
and I couldn't find any where hypothyroidism was 
the etiologic factor. I am as aware as you all are of the 
thousands of women who have taken thyroid medica­
tion as treatment for amenorrhea. but in the patients· 
charts to which I had access. I could not find one 
where this was the real etiologic factor. I did find 
the following case of hyperthyroidism. 
Case 2. This was a 30-year-old gravida 11, para I 
who had had amenorrhea for two years after a spon­
taneous abortion. She had moderate hirsutism. but 
no other virilizing signs. An endometrial biopsy 
showed "resting endometrium," that is. proliferative 
glands without mitotic activity. Thyroid studies were 
normal. and two urinary 17-ketosteroid deter­
minations were moderately elevated: 16.1 and 18.1 
mg/24 hours. It was decided that this was a case of 
adrenal androgenic hyperfunction. The patient was 
initially treated with dexamethasone 2 mg three 
times a day for 2 days. followed by 0.75 mg/day 
for maintenance. Ultimately. this was reduced to 
0.5 mg/day. Under this treatment, the urinary 17-
ketosteroids fell to 2. 7 mg/24 hours. Ovulatory 
cycles began and conception occurred. 
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Case 3. This was a 26-year-old gravida 11. para 2 
who was seen because or amenorrhea and galac­
torrhea since her last delivery two years earlier. This 
patient had been worked up about a year pre­
viously elsewhere and had had normal skull x-rays. 
normal visual fields. and normal EEG. The skull 
x-rays were repeated: this time a destructive lesion 
of the sella was seen. and the visual tields had a 
bilateral defect. A transsphenoidal removal or pru­
lactin-producing pituitary adenoma was done leaving 
the remainder of the pituitary gland. Following this. 
spontaneous menses have returned and they are 
ovulatory. The visual fields have also returned tu 
normal. 
The first three cases dealt with patients who had 
organic diseases of extragenital endocrine glands. 
The remaining four cases have nu identiliable ex­
lragenital endocrine disease. 
Case 4. This was a 20-year-uld gravida O "hose 
menses began at age 13 and had occurred every 35 
days lasting 7 days until two years earlier when 
amenorrhea had begun. coinciding with the lirst year 
of college. She had a history or having received 
thyroid medication in the past although she had 
received none for the preceding year. The l"ree T, was 
1.5 mg%. a normal value. and the maturation index 
was 0/65/35. Oral medroxyprogesterone was admin­
istered. and the patient had withdrawal bleeding 
after this. An extensive investigation was not dune. 
but the medroxyprogesterone medication was con­
tinued for 3 months. After this. spontaneous 
cycles returned. 
Patients who have endogenous estrogen can 
usually be treated with only a pure progestin given at 
monthly intervals. It is unlikely that they have 
anything seriously wrong with their hypothalamic­
pituitary axis. When given an exogenous progestin at 
monthly intervals (we usually give medroxyproges­
terone for 5 days beginning al cycle day 22). 
monthly bleeding episodes usually result. Some 
women who do not want to menstruate 13 times 
a year will be given the medication two 10 rour 
limes a year. I do not think it is good for endu­
metrium to be continuously stimulated by estrogen. 
whether it is endogenous or exogenous. because ur 
the possibility of endometrial hyperplasia. and I 
think that even if the woman is not enthusiastic 
about menstruating, she should be given this medi­
cation at least several times a year. 
Case 5. This was an 18-year-old gravida O who 
had onset or menses at age 10 and who had had 
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menses every 31 days lasting 5 days until she 
entered college. Prior to this, she had experienced 
amenorrhea in the summer when she had gone 
away to camp. but the amenorrhea had ceased 
when she returned home. She had very slight 
hirsutism. and there was no withdrawal bleeding 
after medroxyprogesterone. The serum FSH and LH 
were normal. Tests of thyroid function. skull x-rays. 
and urinary 17-ketosteroids were normal. The patient 
was treated with cyclic estrogens and progestins 
(conjugated estrogens 1.25 mg daily for 21 days 
with medroxyprogesterone 10 mg daily added on 
treatment days 17-21). 
The failure of withdrawal bleeding after 
medruxyprogesterone alone in a patient who does 
have "·ithdrawal bleeding after estrogen-priming be­
fore a prugestin is given indicates lack of endo­
genous estrogen production. The group or patients 
without endogenous estrogen includes cases where 
the defect is ovarian (such as agenesis. castration. 
or premature menopause) as well as cases or pitui­
tary failure (such as that secondary to defective 
releasing factors. ablation by surgery or radiation. 
and diseases such as Sheehan·s syndrome). If this 
syndrome appears at a time when it is appropriate 
for a woman to stop menstruating. as would be the 
case if she were in her mid-40's. I don't think the 
condition necessarily needs to be treated. Certainly 
when it occurs in an 18-year-old girl. as this did. 
I believe that it is reasonable to treat with estro­
gen plus a progestin. This will result in regular 
episodes of withdrawal bleeding. 
Case 6. This was a 27-year-old gravida I. para I 
who had become pregnant the first time without 
dilliculty. but who had had amenorrhea for six years. 
She desired pregnancy. She weighed 208 pounds. had 
mild facial hirsutism. and normal adnexa. Urinary 
17-ketosteroids were 4.4 mg/24 hours. a normal 
value. The maturation index was 0/86/14: a Rubin's 
test had shown tubal patency. and a postcoital test 
had shown abundant sperm. After medroxyproges­
lerone-induced withdrawal bleeding. this patient 
was given clomiphene 50 mg daily for 5 days. and 
she promptly became pregnant in the first month 
of treatment. 
When clomiphene is used. the pregnancy rate 
will he around 30%. The incidence or ovulation is 
much greater than 30%. but every patient who shows 
evidence or ovulation does nut always become preg­
nant. This may be due to the fact that we think the 
p..:rsun is ovulating when she really is nut. All of our 
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indices for detection of ovulation are based on the 
effects of progesterone, because we know that in nor­
mal women progesterone is present and exerts its 
effect primarily after ovulation, and we assume that 
this also happens in abnormal states. I am not ab­
solutely sure that this is so, but I have no valid proof 
that it is not. Ovulation apparently is induced. or at 
least progesterone is produced, in about 70% of the 
women receiving clomiphene, but pregnancy occurs 
only in about 30%. 
Sometimes couples will want to know when is 
the best time for exposure after clomiphene to 
achieve a pregnancy. It is my practice to tell the 
patients to begin having regular intercourse about 
four days after the last tablet and to continue this un­
til the basal temperature has been up for three days. 
Clomiphene is not without side effects. Ovarian 
enlargement may occur in about 14% of patients. and 
sometimes the ovaries become quite large. but the 
problem is much less than with the agent that will be 
dis�ssed shortly. Hot flashes are the common com­
plaint that patients report. If patients are reassured 
about this and told that they are not menopausal. it 
does not seem to be a troublesome effect. The in­
stance of multiple pregnancy is increased tenfold. 
Under normal circumstances. the incidence of multi­
ple pregnancy is around I in 80: with clomiphene it 
will rise to around I in IO or I in 12. Blurring of vi­
sion may occur in around I% of patients. and when 
this occurs. it is an indication to discontinue the 
medication. Spontaneous abortion occurs at a higher 
rate than would be expected. 
Case 7. This was a 29-year-old gravida I. para I. 
aborta O who desired pregnancy and who had had 
amenorrhea for nine months when she was first seen. 
She had been on oral contraceptive medication prior 
to her first pregnancy: this had been discontinued. 
and she had conceived promptly without difficulty. 
After that pregnancy, she took combination oral con­
traceptive tablets for several years. Her other work­
up had indicated that her thyroid function was nor­
mal, that the blood FSH and LH were normal. and 
that 17-ketosteroids were also normal. Tubal patency 
and sperm production were adequate. Attempts to in­
duce ovulation with clomiphene began with a low 
dose of 50 mg daily for 5 days. This was raised 
gradually to 200 mg/day for 5 days, with chorionic 
gonadotropin added after this. This was not 
successful; then treatment with menopausal-chori­
onic gonadotropin was given according to the 
outline in Table I. 
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TABLE I 
Outline of Gonadotropin Rx 
Cervical Plasma 
lb Day Mucus Estradiol Rx 
I 0 HMG 75-75 u. 
0 HMG 150-150u. 
.1 0 HMG 150-150u. 
4 I+ HMG 150-150u. 
I+ 1.14 pg/ml HMG 150-150u. 
2+ 179 pg/ml H MG 225-225 u. 
2+ 2.17 pg/ml HMG 300-300 u. 
8 3+ 332 pg/1111 HMG 300-300 u. 
9 H 478 pg/ml HMG 300-300 u. 
10 4+ 938 pg/ml HMG 10.000u. 
II 
12 BBT down 
13 Sustained rise in BBT began. followed by menses. 
1 n such cases. one may get response to 
menopausal plus chorionic gonadotropin. The in­
stance of pregnancy with this treatment is around 
25%. This treatment is also associated with side 
effects. One has to be very careful in giving it. 
Ovarian enlargement may occur in up to 20% of the 
cases. and in extreme instances may be associated 
with acites and even plural effusions. The cysts 
may rupture. and there may be hemoperitoneum. 
The severe hyperstimulation syndrome is found to 
be associated with abdominal distention and 
hemoconcentration (because so much of the body's 
total fluid volume has gone into the abdominal 
cavity). The treatment is bedrest. intravenous fluids 
with close monitoring of electrolytes. and avoid­
ance of pelvic examinations. This can become 
serious. can lead to thrombosis. and there have been 
several deaths. The instance of multiple pregnancy 
with menopausal-chorionic gonadotropin treatment 
is 20-37%. and the instance of abortion is around 
28%: an incidence greater than would be expected 
with normal spontaneous ovulation. In one series, it 
was found that three-fourths of the multiple pregnan­
cies were twins. and one-fourth of the multiple preg­
nancies were three or more. 
There are several problems in treating women 
with gonadotropins. One wants to give enough 
medication to induce ovulation, but not so much that 
the hyperstimulation syndrome is produced. In 
this particular patient, the menopausal gonadotropin 
dosage was gradually increased until day IO when 
good cervical mucus was seen, indicating that, 
more than likely, enough medication had been. 
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given. Laboratory tests of estrogen production 
were done to determine that too much had not 
been given. In many institutions. the determination is 
of urinary estrogen. but at the Medical College or 
Virginia there is a technique whereby plasma es­
tradiol can be measured in about six hours. The 
patients have blood drawn in the morning and return 
at 4:00 p.m .. at which time the laboratory data is 
available. The aim is to reach a level or between 500 
and IOOO pg/ml of estradiol. If the level stays un­
der IOOO pg/1111. the incidence of hyperstirnulation 
syndrome is much less than if the level is higher. 
If this patient had been given another day or treat­
ment. a situation might have been created where 
hyperstimulation would have occurred. The patient 
did not become pregnant. although evidence for 
ovulation was obtained from basal temperature 
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charts. I want to emphasize this because I think this is 
a way a physician can get in trouble. One can decide 
when he has given enough estrogen by the effect on 
cervical mucus. but one cannot tell when he has given 
too much. If est radio I levels are too high, one would 
not give chorionic gonadotropin, stop the treatment, 
and try again in a month or so, giving less medi­
cation. I think to avoid serious complications in 
treating a nonlethal condition. there has to be some 
way of assessing the estrogen production from the 
stimulated ovaries. 
I have tried to illustrate the treatment for 
amenorrhea of different causes and to emphasize the 
fact that the treatment is different when the woman 
wishes or does not wish to become pregnant. I have 
also pointed out some of the hazards of the various 
methods of treatment of this condition. 
